These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37872122)

  • 1. Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
    Tu YP; Hanze E; Zhu F; Lagraauw HM; Sloss CM; Method M; Esteves B; Westin EH; Berkenblit A
    Br J Clin Pharmacol; 2024 Feb; 90(2):568-581. PubMed ID: 37872122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
    Nwabufo CK
    Cancer Chemother Pharmacol; 2024 Feb; 93(2):89-105. PubMed ID: 37594572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
    Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
    Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis.
    Wang Y; Liu L; Jin X; Yu Y
    Crit Rev Oncol Hematol; 2024 Feb; 194():104230. PubMed ID: 38122916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
    Coleman RL; Lorusso D; Oaknin A; Cecere SC; Denys H; Colombo N; van Gorp T; Konner JA; Romeo Marin M; Harter P; Murphy C; Wang Y; Esteves B; Method M; Matulonis U
    Int J Gynecol Cancer; 2024 Aug; 34(8):1119-1125. PubMed ID: 38858103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
    J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
    Moore KN; Vergote I; Oaknin A; Colombo N; Banerjee S; Oza A; Pautier P; Malek K; Birrer MJ
    Future Oncol; 2018 Jul; 14(17):1669-1678. PubMed ID: 29424243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM
    Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirvetuximab Soravtansine: First Approval.
    Heo YA
    Drugs; 2023 Feb; 83(3):265-273. PubMed ID: 36656533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
    Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
    Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.
    Porter RL; Matulonis UA
    Expert Rev Anticancer Ther; 2023; 23(8):783-796. PubMed ID: 37458180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Moore KN; Oza AM; Colombo N; Oaknin A; Scambia G; Lorusso D; Konecny GE; Banerjee S; Murphy CG; Tanyi JL; Hirte H; Konner JA; Lim PC; Prasad-Hayes M; Monk BJ; Pautier P; Wang J; Berkenblit A; Vergote I; Birrer MJ
    Ann Oncol; 2021 Jun; 32(6):757-765. PubMed ID: 33667670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
    Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
    Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
    Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
    Bogani G; Coleman RL; Vergote I; van Gorp T; Ray-Coquard I; Oaknin A; Matulonis U; O'Malley D; Raspagliesi F; Scambia G; Monk BJ
    Int J Gynecol Cancer; 2024 Apr; 34(4):469-477. PubMed ID: 38101816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
    Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
    Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.